Yu-Waye Chu
Overview
Explore the profile of Yu-Waye Chu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hosseini I, Gadkar K, Stefanich E, Li C, Sun L, Chu Y, et al.
NPJ Syst Biol Appl
. 2020 Aug;
6(1):28.
PMID: 32859946
Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However, potent immune stimulation with T-cell...
2.
Morschhauser F, Flinn I, Advani R, Sehn L, Diefenbach C, Kolibaba K, et al.
Lancet Haematol
. 2019 Apr;
6(5):e254-e265.
PMID: 30935953
Background: Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 study was...
3.
Zhu R, Lu D, Chu Y, Chai A, Green M, Zhang N, et al.
AAPS J
. 2017 Feb;
19(3):669-681.
PMID: 28224402
Correlations between early and late efficacy endpoints were assessed to identify potential surrogate endpoints for overall survival (OS) or progression-free survival (PFS) with clinical trial-level data in three non-Hodgkin lymphoma...
4.
Leong S, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, et al.
Blood
. 2016 Dec;
129(5):609-618.
PMID: 27908880
Acute myeloid leukemia (AML) is a major unmet medical need. Most patients have poor long-term survival, and treatment has not significantly changed in 40 years. Recently, bispecific antibodies that redirect...
5.
Advani R, Lebovic D, Chen A, Brunvand M, Goy A, Chang J, et al.
Clin Cancer Res
. 2016 Sep;
23(5):1167-1176.
PMID: 27601593
Pinatuzumab vedotin is an antibody-drug conjugate with the potent antimicrotubule agent monomethyl auristatin E (MMAE) conjugated to an anti-CD22 antibody via a protease-cleavable linker. This phase I study determined its...
6.
Gupta M, Wang B, Carrothers T, LoRusso P, Chu Y, Shih T, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
2(1):11-24.
PMID: 27121556
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in development for human epidermal growth factor receptor 2 (HER2)-positive cancer. Drugs in development are generally tested for their effects on QT interval,...
7.
Sun L, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al.
Sci Transl Med
. 2015 May;
7(287):287ra70.
PMID: 25972002
Bispecific antibodies and antibody fragments in various formats have been explored as a means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been reported with...
8.
Palanca-Wessels M, Czuczman M, Salles G, Assouline S, Sehn L, Flinn I, et al.
Lancet Oncol
. 2015 May;
16(6):704-15.
PMID: 25925619
Background: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated...
9.
Li D, Poon K, Yu S, Dere R, Go M, Lau J, et al.
Mol Cancer Ther
. 2013 Apr;
12(7):1255-65.
PMID: 23598530
Antibody-drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S...
10.
Chu Y, Polson A
Future Oncol
. 2013 Mar;
9(3):355-68.
PMID: 23469971
Antibody-drug conjugates (ADCs) are a broad class of molecules comprising of a potent cytotoxic agent conjugated with a monoclonal antibody using a chemically stable linker. By selecting a monoclonal antibody...